mosapride has been researched along with Cirrhosis, Liver in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, D; Feng, H; Liu, Y; Xiong, J; Xu, H; Xu, J | 1 |
| Asano, T; Fujishiro, M; Fukushima, T; Iwashita, M; Kamata, H; Kushiyama, A; Matsunaga, Y; Nakatsu, Y; Nishimura, F; Ohno, H; Okubo, H; Sakoda, H; Shinjo, T; Yoneda, M | 1 |
1 trial(s) available for mosapride and Cirrhosis, Liver
| Article | Year |
|---|---|
The influence of mosapride on gut microbiota of carbon tetrachloride-induced cirrhosis rats based on 16S rRNA gene sequencing.
Topics: Animals; Bacteria; Benzamides; Carbon Tetrachloride; Gastrointestinal Microbiome; Genes, rRNA; Liver Cirrhosis; Male; Morpholines; Rats; Rats, Sprague-Dawley; RNA, Ribosomal, 16S | 2022 |
1 other study(ies) available for mosapride and Cirrhosis, Liver
| Article | Year |
|---|---|
Mosapride citrate improves nonalcoholic steatohepatitis with increased fecal lactic acid bacteria and plasma glucagon-like peptide-1 level in a rodent model.
Topics: Animals; Benzamides; Choline Deficiency; Feces; Gastrointestinal Tract; Glucagon-Like Peptide 1; Inflammation; Lactic Acid; Liver; Liver Cirrhosis; Mice, Inbred C57BL; Morpholines; Non-alcoholic Fatty Liver Disease | 2015 |